Back to Search
Start Over
Pharmacological inhibition of Hippo pathway, with the novel kinase inhibitor XMU-MP-1, protects the heart against adverse effects during pressure overload.
- Source :
- British Journal of Pharmacology; Oct2019, Vol. 176 Issue 20, p3956-3971, 16p, 5 Color Photographs, 2 Charts, 2 Graphs
- Publication Year :
- 2019
-
Abstract
- <bold>Background and Purpose: </bold>The Hippo pathway has emerged as a potential therapeutic target to control pathological cardiac remodelling. The core components of the Hippo pathway, mammalian Ste-20 like kinase 1 (Mst1) and mammalian Ste-20 like kinase 2 (Mst2), modulate cardiac hypertrophy, apoptosis, and fibrosis. Here, we study the effects of pharmacological inhibition of Mst1/2 using a novel inhibitor XMU-MP-1 in controlling the adverse effects of pressure overload-induced hypertrophy.<bold>Experimental Approach: </bold>We used cultured neonatal rat cardiomyocytes (NRCM) and C57Bl/6 mice with transverse aortic constriction (TAC) as in vitro and in vivo models, respectively, to test the effects of XMU-MP-1 treatment. We used luciferase reporter assays, western blots and immunofluorescence assays in vitro, with echocardiography, qRT-PCR and immunohistochemical methods in vivo.<bold>Key Results: </bold>XMU-MP-1 treatment significantly increased activity of the Hippo pathway effector yes-associated protein and inhibited phenylephrine-induced hypertrophy in NRCM. XMU-MP-1 improved cardiomyocyte survival and reduced apoptosis following oxidative stress. In vivo, mice 3 weeks after TAC, were treated with XMU-MP-1 (1 mg·kg-1 ) every alternate day for 10 further days. XMU-MP-1-treated mice showed better cardiac contractility than vehicle-treated mice. Cardiomyocyte cross-sectional size and expression of the hypertrophic marker, brain natriuretic peptide, were reduced in XMU-MP-1-treated mice. Improved heart function in XMU-MP-1-treated mice with TAC, was accompanied by fewer TUNEL positive cardiomyocytes and lower levels of fibrosis, suggesting inhibition of cardiomyocyte apoptosis and decreased fibrosis.<bold>Conclusions and Implications: </bold>The Hippo pathway inhibitor, XMU-MP-1, reduced cellular hypertrophy and improved survival in cultured cardiomyocytes and, in vivo, preserved cardiac function following pressure overload. [ABSTRACT FROM AUTHOR]
- Subjects :
- KINASE inhibitors
APOPTOSIS inhibition
CARDIAC hypertrophy
BRAIN natriuretic factor
CELL metabolism
ANIMAL experimentation
APOPTOSIS
CELL culture
CELL physiology
CELLS
COMPARATIVE studies
RESEARCH methodology
MEDICAL cooperation
MICE
PRESSURE
RATS
RESEARCH
SULFONAMIDES
TRANSFERASES
EVALUATION research
PROTEIN kinase inhibitors
PHARMACODYNAMICS
Subjects
Details
- Language :
- English
- ISSN :
- 00071188
- Volume :
- 176
- Issue :
- 20
- Database :
- Complementary Index
- Journal :
- British Journal of Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 139295025
- Full Text :
- https://doi.org/10.1111/bph.14795